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ABSTRACT

Provided are tris-quatemary ammonium compounds Which
are modulators of nicotinic acetylocholine receptors. Also
provided are methods of using the compounds for modulating
the function of a nicotinic acetylcholine receptor, and for the
prevention and/ or treatment of central nervous system disor
ders, substance use and/or abuse and or gastrointestinal tract

disorders.
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TRIS-QUARTERNARY AMMONIUM SALTS

these neurotransmitter systems. NIC facilitates neurotrans

AND METHODS FOR MODULATING
NEURONAL NICOTINIC ACETYLCHOLINE
RECEPTORS

mitter release from nerve terminals.

The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of inter

est in developing novel, subtype-selective agonists and/or
antagonists. Some of these agonists are currently being evalu

FIELD OF THE INVENTION

ated in clinical trials for cognitive enhancement and neuro

protective effects, potentially bene?cial for disease states

The invention relates to tris-quatemary ammonium salts
and their use in modulating nicotinic acetylcholine receptors.

such as AlZheimer’s and Parkinson’s disease.
10

BACKGROUND OF THE INVENTION

SUMMARY OF INVENTION

S(—)-nicotine (NIC) activates presynaptic andpostsynaptic

In one embodiment, compounds corresponding to the fol
loWing structure are provided.

neuronal nicotinic receptors that evoke the release of neu

(I)

to
//
rotransmitters from presynaptic terminals and that modulate 25 The three side chains attached to the phenyl ring may be
connected to the l, 2, and 3 positions; the l, 2, and 4
the depolariZation state of the postsynaptic neuronal mem

positions; or the l, 3 and 5 positions of the phenyl ring.
The values for ml, m2 and m3 are each independently 0, l, 2,

brane, respectively. Thus, nicotine produces its effect by
binding to a family of ligand-gated ion channels, stimulated
by acetylcholine (ACh) or nicotine Which causes the ion

3, 4 or 5.

channel to open and cations to ?ux With a resulting rapid 30

(millisecond) depolarization of the target cell.

4 or 5.

X19, X29, and X39 are each independently an organic or

Neuronal nicotinic receptors are composed of tWo types of

inorganic anion.

subunits, 0t and [3, and assemble as heteromeric receptors With
the general stoichiometry of 2a and 3[3 or as homomeric
receptors With 5a subunits. Nine subtypes of the ot subunit

L1, L2 and L3 are each independently chosen from the group
consisting of 4CH24CH2i, cis iCH:CHi, trans

iCH:CHi, iCECi, %H2iSi, iSiCHZi,
iSeiCHzi,
iCHZiSei,
%H2A)i,
iO%H2i, iCHziNHi, iNHiCHzi, %H2i

(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are
found in the central nervous system. The mo st common nico

tinic receptor subtype in the brain is composed of tWo (X4 and

NRi Where R is a branched or straight chain alkyl group
of one to four carbons, iNRiCHZi Where R is a
branched or straight chain alkyl group of one to four car

three [32 subunits, i.e., (X462. These subunits display different,
but overlapping, patterns of expression in the brain. Examples
of heteromeric receptor subtypes include (X462, (X362, (X3 [34,

bons, 4CH:Ni, iN:CHi, and iN:Ni.

(X662, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and
others. The predominant homomeric subtype includes (x7, but
other combinations have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combina
tions of assemblies of subunits into functional receptor pro
teins, Which affords a Wide diversity of pharmacological

The values for n1, n2, and n3 are each independently l, 2, 3,

R1, R2, and R3 are each independently ?ve or six membered
nitrogen containing rings as shoWn in formulas (IIA) and

(IIB).
45

(HA)

50

speci?city.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3H]NIC

(IIB)

appears to label the same sites in the brain as [3H]ACh. It has

been estimated that over 90% of [3H]NIC binding in the brain
is due to association With the heteromeric receptor that is
composed of (X4 and [32 subunits. Also abundant in the central
nervous system are the homomeric receptors labeled by [3 H]

methyllycaconitine (MLA), Which has high af?nity for the (X7
nicotinic receptor subtype. Nicotinic receptor subtypes can

OO

be studied using functional assays, such as NIC-evoked neu

rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H]
norepinephrine (NE) release, [3H]serotonin (5-HT) release,
[3 H] gamma-aminobutyric acid (GABA) release and [3 H]
glutamate release) from superfused rat brain slices. Nicotinic
receptors are located in the cell body and terminal areas of

Al is carbon or nitrogen, provided that When A1 joins a ring
65

atom With an unsaturated bond or is a nitrogen, R9 is ab sent,
and When A1 joins a ring atom an unsaturated bond and is
a nitrogen, both R4 and R9 are absent.
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selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk

A2 is carbon or nitrogen, provided that When A2 joins a ring
atom an unsaturated bond or is a nitrogen, R10 is absent,
and When A2 joins a ring atom an unsaturated bond and is
a nitrogen, both R5 and R10 are absent.

enyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted ary

A3 is carbon or nitrogen, provided that When A3 joins a ring

lalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl,
substituted arylalkynyl, acyl, substituted acyl, alkylsulfo

atom an unsaturated bond or is a nitrogen, R11 is absent,
and When A3 joins a ring atom an unsaturated bond and is
a nitrogen, both R6 and R1 l are absent.

nyl, arylsulfonyl, heterocyclic, or substituted heterocyclic,
Where if Y4 or Y5 comprises alkenyl or alkynyl, the site of

A4 is carbon or nitrogen; provided that When A4 joins a ring

unsaturation is not conjugated With the nitrogen; SY6,
Where Y6 is selected from hydrogen, alkyl, substituted

atom an unsaturated bond or is a nitrogen, R12 is absent,
and When A4 joins a ring atom an unsaturated bond and is
a nitrogen, both R7 and R12 are absent.

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substi
tuted alkenyl, alkynyl, substituted alkynyl, aryl, substituted
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted

A5 is carbon or nitrogen, provided that When A5 joins a ring

arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl,

atom an unsaturated bond or is a nitrogen, R13 is absent,
and When A5 joins a ring atom an unsaturated bond and is
a nitrogen, both R8 and R13 are absent.

substituted arylalkynyl, heterocyclic, or substituted hetero

cyclic, and Where if Y6 comprises alkenyl or alkynyl, the

A6 is carbon or nitrogen, provided that When A6 joins a ring

site of unsaturation is not conjugated With the sulfur; or R4

atom an unsaturated bond or is a nitrogen, R19 is absent,
and When A6 joins a ring atom an unsaturated bond and is
a nitrogen, both R15 and R19 are absent.

and R5 together WithAl and A2, or R5 and R6 together With
A2 and A3, or R15 and R16 together With A6 and A7, or R16
and R17 together WithA7 andA8 independently form a three
to eight member cycloalkane, substituted cycloalkane,

20

A7 is carbon or nitrogen, provided that When A7 joins a ring

cycloalkene, substituted cycloalkene, aryl, substituted

atom an unsaturated bond or is a nitrogen, R20 is absent,
and When A7 joins a ring atom an unsaturated bond and is
a nitrogen, both R16 and R20 are absent.

A8 is carbon or nitrogen, provided that When A8 joins a ring

aryl, heterocycle With one to three hetero atoms in the ring,
or substituted heterocycle With one to three hetero atoms in
25

atom an unsaturated bond or is a nitrogen, R21 is absent,
and When A8 joins a ring atom an unsaturated bond and is
a nitrogen, both R17 and R21 are absent.

In another embodiment, a composition is provided com
prising a pharmaceutically acceptable carrier and a com
pound as described above.
In another embodiment, a method is provided for selec

A9 is carbon or nitrogen, provided that When A9 joins a ring
atom an unsaturated bond or is a nitrogen, R22 is absent,
and When A9 joins a ring atom an unsaturated bond and is

30

a nitrogen, both R18 and R22 are absent.
R14 or R23 is absent When any of the bonds to the ammonium
nitrogen is unsaturated, and R14 or R23 is a straight chain or
branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

the ring.

tively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective
amount of a compound as described above to a mammalian

subject in need thereof.
In another embodiment, a method is provided for prevent
35

ing and/ or treating a central nervous system associated disor

der comprising administering a therapeutically effective

R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16, R17’

amount of a compound as described above to a mammalian

R18, R19, R20, R21, and R22, When present, are each inde
pendently selected from hydrogen; alkyl; substituted alkyl;
cycloalkyl; substituted cycloalkyl; alkenyl; substituted alk
enyl; alkynyl; substituted alkynyl; aryl; substituted aryl;
alkylaryl; substituted alkylaryl; arylalkyl; substituted ary

subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/or treating substance use and/or abuse comprising

lalkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl;
substituted arylalkynyl; heterocyclic; substituted heterocy
clic; halo; cyano; nitro; SOY1, SOZYI, SOZOYl or

40

administering a therapeutically effective amount of a com

pound as described above to a mammalian subject in need
thereof.

In another embodiment, a method is provided for prevent
45

SO2NHYl, where Y1 is selected from hydrogen, loWer
alkyl, alkenyl, alkynyl or aryl, and where Y1 is not hydro
gen in SOYl and if Y1 is alkenyl or alkynyl, the site of
unsaturation is not conjugated With a heteroatom; COY2,
Where Y2 is selected from hydrogen, alkyl, substituted

administering a therapeutically effective amount of a com

pound as described above to a mammalian subject in need
thereof.

Other methods, features and advantages of the present
50

alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl,

invention Will be or become apparent to one With skill in the

art upon examination of the folloWing detailed descriptions. It
is intended that all such additional methods, features and
advantages be included Within this description, be Within the
scope of the present invention, andbe protected by the accom

substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, heterocyclic, or sub
stituted heterocyclic, and Where ifY2 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the

ing and/ or treating gastrointestinal tract disorders comprising

55

panying claims.
BRIEF DESCRIPTION OF THE DRAWINGS

carbonyl group; OY3 , Where Y3 is selected from hydrogen,

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, ary
lalkyl, substituted arylalkyl, arylalkenyl, substituted aryla
lkenyl, arylalkynyl, substituted arylalkynyl, acyl, substi
tuted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or
substituted heterocyclic, Where if Y3 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
oxygen; NY4Y5, Where Y4 and Y5 are each independently

FIG. 1 shoWs concentration-response curves for GZ551A
60

in each four subtypes of nicotinic receptor (a462, 0662,

0664 and (X7) expressed in Xenopus oocyles.
FIG. 2 shoWs concentration-response curves for GZ551B

in each four subtypes of nicotinic receptor (a462, 0662,

0664 and (X7) expressed in Xenopus oocyles.
65

FIG. 3 shoWs concentration-response curves for GZ558C

in each four subtypes of nicotinic receptor (a462, 0662,

0664 and (X7) expressed in Xenopus oocyles.

US 8,299,253 B2
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The term “alkyl” refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and “substituted alkyl”

FIG. 4 shows the inhibitory response of the (X7 nicotinic

receptor subtype expressed in Xenopus oocyles to 1.0 mM
analog concentration for 17 analogs co-applied With 60 mM
acetylcholine (?lled bars), as Well as recovery from analog
induced inhibition following Washing of the preparation

refers to alkyl radicals further bearing one or more substitu

ents including, but not limited to, hydroxy, alkoxy (of a loWer

alkyl group), mercapto (of a loWer alkyl group), aryl, hetero
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car
boxyl, carbamate, sulfonyl, and sulfonamide.

(open bars).

The term “cycloalkyl” refers to cyclic ring-containing moi
DETAILED DESCRIPTION OF INVENTION

eties containing 3 to 8 carbon atoms, and “substituted
cycloalkyl” refers to cycloalkyl moieties further bearing one

Before the present compositions and methods are
described, it is to be understood that the invention is not

or more substituents as set forth above.

and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

The term “alkenyl” refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon double
bond and having 2 to 19 carbon atoms, and “substituted
alkenyl” refers to alkenyl groups further bearing one or more

describe particular embodiments of the present invention, and

substituents as set forth above.

limited to the particular methodologies, protocols, assays,

The term “alkynyl” refers to straight or branched chain

is in no Way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

hydrocarbyl moieties having at least one carbon-carbon triple
bond and having 2 to 19 carbon atoms, and “substituted
alkynyl” refers to alkynyl moieties further bearing one or

claims, the singular forms “a,” “an,” and “the” include plural
references unless the context clearly dictates otherwise.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to Which this invention
belongs. All publications cited herein are incorporated herein

20

The term “aryl” refers to aromatic groups having 6 to 24
carbon atoms, and “substituted aryl” refers to aryl groups
further bearing one or more substituents as set forth above.

The term “alkylaryl” refers to alkyl-substituted aryl
groups, and “substituted alkylaryl” refers to alkylaryl groups

by reference in their entirety for the purpose of describing and

disclosing the methodologies, reagents, and tools reported in

more substituents as set forth above.

25

further bearing one or more substituents as set forth above.

invention. Nothing herein is to be construed as an admission

The term “arylalkyl” refers to aryl-substituted alkyl
groups, and “substituted arylalkyl” refers to arylalkyl groups

that the invention is not entitled to antedate such disclosure by

further bearing one or more substituents as set forth above.

the publications that might be used in connection With the

virtue of prior invention.
The term “nicotinic acetylcholine receptor” refers to the

30

The term “arylalkenyl” refers to aryl-substituted alkenyl
groups, and “substituted arylalkenyl” refers to arylalkenyl

endogenous acetylcholine receptor having binding sites for

groups further bearing one or more substituents as set forth

acetylcholine Which also bind to nicotine. The term “nicotinic
acetylcholine receptor” includes the term “neuronal nicotinic

above.
The term “arylalkynyl” refers to aryl-substituted alkynyl
groups, and “substituted arylalkynyl” refers to arylalkynyl

acetylcholine receptor.”
The terms “subtype of nicotinic acetylcholine receptor,”
and “nicotinic acetylcholine receptor subtype” refer to vari

35 groups further bearing one or more substituents as set forth

above.
The term “heterocyclic” refers to cyclic moieties contain

ous subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or hetero
meric complex, or multiple homomeric or heteromeric com

plexes.
The term “agonist” refers to a substance Which interacts
With a receptor and increases or prolongs a physiological

ing one or more heteroatoms as part of the ring structure and

having 3 to 24 carbon atoms, and “substituted heterocyclic”
40

The term “acyl” refers to alkyl-carbonyl groups, and “sub
stituted acyl” refers to acyl groups further bearing one or

response (i.e. activates the receptor).
The term “partial agonist” refers to a substance Which
interacts With and activates a receptor to a lesser degree than
an agonist.
The term “antagonist” refers to a substance Which interacts
With and decreases the extent or duration of a physiological

response of that receptor.
The terms “disorder,” “disease,” and “condition” are used
inclusively and refer to any status deviating from normal.

more substituents as set forth above.
45

50

The term “central nervous system associated disorders”

alkyl radicals having in the range of l to 4 carbon atoms.

The term “halogen” refers to ?uoride, chloride, bromide or
iodide groups.
It is understood that in all substituted groups de?ned above,

polymers arrived at by de?ning sub stituents With further sub
stituents to themselves (e. g. substituted aryl having a substi

includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated With the alteration of normal
neurotransmitter release in the brain.
The term “loWer alkyl” refers to straight or branched chain

refers to heterocyclic moieties further bearing one or more
substituents as set forth above.

tuted aryl group as a substituent Which is itself substituted
With a substituted aryl group, etc.) are not intended for inclu
sion herein. In such cases, the maximum number of such
substituents is three. That is to say that each of the above

de?nitions is constrained by a limitation that, for example,
substituted aryl groups are limited to -substituted aryl-(sub
55

stituted aryl)-sub stituted aryl.
Compounds of the present invention are tris-quaternary
ammonium salts corresponding to Formula (I):
(1)

to
//
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7
The three side chains attached to the phenyl ring may be

and When A7 joins a ring atom With an unsaturated bond and
is a nitrogen, both R16 and R20 are absent.

connected to the 1, 2, and3 positions; the 1, 2, and 4 positions;
or the 1, 3 and 5 positions of the phenyl ring.
The values for m1, m2 and m3 are each independently 0, 1,

A8 is carbon or nitrogen, provided that WhenA8 joins a ring
atom With an unsaturated bond or is a nitrogen, R21 is absent,
and When A8 joins a ring atom With an unsaturated bond and
is a nitrogen, both R17 and R21 are absent.

2, 3, 4 or 5.

The values for n1, n2, and n3 are each independently 1, 2,

A9 is carbon or nitrogen, provided that WhenA9 joins a ring

3, 4 or 5.

X19, X29, and X39 are each independently an organic or

atom With an unsaturated bond or is a nitrogen, R22 is absent,
and When A9 joins a ring atom With an unsaturated bond and
is a nitrogen, both R18 and R22 are absent.
R14 or R23 is absent When any of the bonds to the ammo

inorganic anion.
Ll, L2 and L3 are each independently chosen from the
group consisting of 4CH24CH2i, cis 4CH:CHi,
trans
4CH:CHi,
4CECi,
iCHZiSi,

nium nitrogen is unsaturated, and R14 or R23 is a straight chain

iSiCHZi, iseiCHzi, %H2iSei, %H2A)i,
iO%H2i, iCHziNHi, iNH%H2i, %H2i

or branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

NRi Where R is a branched or straight chain alkyl group of

R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16,

one to four carbons, iNR4CH2i Where R is a branched or

straight chain alkyl group of one to four carbons,
iCH:Ni, iN:CHi, and iN:Ni.
R1, R2, and R3 are each independently ?ve or six membered
nitrogen containing rings as shoWn in formulas (HA) and

20

(11B).
(HA)
25

R17, R18, R19, R20, R21, and R22, When present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, SOYl, SOZYI, SO2OYl or SO2NHY1,
where Y1 is selected from hydrogen, loWer alkyl, alkenyl,
alkynyl or aryl, and WhereYl is not hydrogen in SOYl and if
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju
gated With a heteroatom; COY2, Where Y2 is selected from

30

(HE)
35

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het
erocyclic, or substituted heterocyclic, and Where if Y2 com
prises alkenyl or alkynyl, the site of unsaturation is not

conjugated With the carbonyl group; 0Y3, Where Y3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
40

A1 is carbon or nitrogen, provided that WhenAl joins a ring
atom With an unsaturated bond or is a nitrogen, R9 is absent,
and When A1 joins a ring atom With an unsaturated bond and
is a nitrogen, both R4 and R9 are absent.

45

substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy
clic, or substituted heterocyclic, Where if Y3 comprises alk
enyl or alkynyl, the site of unsaturation is not conjugated With

A2 is carbon or nitrogen, provided that When A2 joins a ring

the oxygen; NY4Y5 , Where Y4 and Y5 are each independently

atom With an unsaturated bond or is a nitrogen, R10 is absent,
and When A2 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R10 are absent.

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy

A3 is carbon or nitrogen, provided that When A3 joins a ring

50

atom With an unsaturated bond or is a nitrogen, R1 l is absent,

and When A3 joins a ring atom With an unsaturated bond and
is a nitrogen, both R6 and R11 are absent.

clic, or substituted heterocyclic, Where ifY4 orY5 comprises

A4 is carbon or nitrogen, provided that When A4 j oins a ring
atom With an unsaturated bond or is a nitrogen, R12 is absent,
and When A4 joins a ring atom With an unsaturated bond and
is a nitrogen, both R7 and R12 are absent.

alkenyl or alkynyl, the site of unsaturation is not conjugated
55

With the nitrogen; SY6, Where Y6 is selected from hydrogen,

60

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or

A5 is carbon or nitrogen, provided that When A5 joins a ring
atom With an unsaturated bond or is a nitrogen, R13 is absent,
and When A5 joins a ring atom With an unsaturated bond and
is a nitrogen, both R8 and R13 are absent.

substituted heterocyclic, and Where ifY6 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6
together With A2 and A3, or R15 and R1 6 together With A6 and

A6 is carbon or nitrogen, provided that When A6 joins a ring
atom With an unsaturated bond or is a nitrogen, R19 is absent,
and When A6 joins a ring atom With an unsaturated bond and
is a nitrogen, both R15 and R19 are absent.

A7 is carbon or nitrogen, provided that When A7 joins a ring
atom With an unsaturated bond or is a nitrogen, R20 is absent,

65

A7, or R16 and R17 together With A7 and A8 independently
form a three to eight member cycloalkane, substituted

cycloalkane, cycloalkene, substituted cycloalkene, aryl, sub

US 8,299,253 B2
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stituted aryl, heterocycle With one to three hetero atoms in the
ring, or substituted heterocycle With one to three hetero atoms

maleate, tartrate, oxalate, succinate, or similar pharmaceuti

in the ring.

pharmaceutically acceptable salts listed in the Journal of

For example, R1, R2, and R3 include pyrrole, pyrrolidine,
pyraZole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine,
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet
rahydroisoquinoline, pyraZine, piperaZine, pyridaZine, and

hereby incorporated by reference. The above salt forms may

cally acceptable organic acid addition salts, including the
Pharmaceutical Sciences Volume 66, page 2, 1977, Which are
be in some cases hydrates or solvates With alcohols and other

solvents.

triaZine.

In a compound of Formula (I), preferably the phenyl ring is

As another example, R4, R5, R6, R7, R8, R9, R10, R11, R12,
R13’ R14’ R15’ R16, R17’ R18, R19’ R20’ R21’ and R22’ include
hydrogen, methyl, ethyl, propyl, butyl, tri?uoromethyl, pyr

substituted at the 1, 3 and 5 positions.

In a compound of Formula (I), preferably A1, A2, A3, A4,
and A5 are carbon.

rolidine, N-alkyl pyrrolidine (for example Where the alkyl

In a compound of Formula (I), preferably R1, R2, and R3
are substituted, six-membered, aromatic rings. More prefer

chain is methyl, ethyl or propyl), unsaturated pyrrolidine,

unsaturated N-alkyl pyrrolidine (for example Where the alkyl
chain is methyl, ethyl or propyl), aZiridine, N-methyl aZiri

ably, R1, R2, and R3 are substituted pyridinium rings.

dine, aZetidine, N-methyl aZetidine, unsaturated aZetidine,
unsaturated N-methyl aZetidine, piperidine, N-methyl piperi
dine, unsaturated piperidine, unsaturated N-methyl piperi

alkyl, or forms an aryl ring With A1, A2 and R5 . More prefer

dine, aZepane, N-methyl aZepane, unsaturated aZepane,
unsaturated N-methyl aZepane, aZocane, N-methyl aZocane,

In a compound of Formula (I), preferably R4 is hydrogen,
ably, R4 is hydrogen, methyl or forms a phenyl group withAl,
A2 and R5 .
20

unsaturated aZocane, unsaturated N-methyl aZocane, 1-aZa

bicyclo[3.2.1]octane, 1-aZa-bicyclo[2.2.1]heptane, 8-me

thyl-8-aZa-bicyclo[3.2.1]octane,

In a compound of Formula (I), preferably R5 is hydrogen,
alkyl, phenyl, 1-methyl-2-pyrrolidinyl, forms a six-mem
bered ring With A1, A2 and R4, or forms an aryl ring With A2,

1-aZa-tricyclo[3.3.1.13’7]

A3 and R6. More preferably, R5 is hydrogen, methyl, butyl,

decane, methyl cycloalkyl, methyl substituted cycloalkyl,

phenyl, 1-methyl-2-pyrrolidinyl, forms a phenyl group With
A1, A2 and R4, or forms a phenyl group With A2, A3 and R6.
In a compound of Formula (I), preferably R6 is hydrogen,
alkyl, or forms an aryl ring With A2, A3 and R5 . More prefer
ably, R6 is hydrogen, methyl or forms a phenyl group WithA2,

methyl pyrrolidine, methyl N-alkyl pyrrolidine (for example

25

Where the alkyl chain is methyl, ethyl or propyl), methyl

unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrroli
dine (for example Where the alkyl chain is methyl, ethyl or

propyl), methyl aZiridine, methyl N-methyl aZiridine, methyl
aZetidine, methyl N-methyl aZetidine, methyl unsaturated
aZetidine, methyl unsaturated N-methyl aZetidine, methyl
piperidine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl

A3 and R5 .
30

aZepane, methyl N-methyl aZepane, methyl unsaturated
aZepane, methyl unsaturated N-methyl aZepane, methyl aZo
cane, methyl N-methyl aZocane, methyl unsaturated aZocane,

35

In a compound of Formula (I), preferably X19, X29, and
X39 are halogens. More preferably, X19, X29, and X39 are
40

bromide.

In one embodiment, the compound of Formula (I) is

As a further example, When R4 and R5 together WithAl and
A2, or R5 and R6 together With A2 and A3, or R15 and R16
together With A6 and A7, or R1 6 and R17 together With A7 and
A8 independently form a three to eight-membered ring, that
ring may be a heterocycle containing up to three hetero atoms

In a compound of Formula (I), preferably m:0.
In a compound of Formula (I), preferably n:3.
In a compound of Formula (I), preferably L1, L2 and L3 are
%H2%H2i or *CECi.

methyl unsaturated N-methyl aZocane, methyl-1 -aZa-bicyclo
[3.2.1]octane, methyl-1-aZa-bicyclo[2.2.1]heptane, 8-me
thyl-8-aZa-bicyclo[3.2.1]octane, and methyl-1-aZa-tricyclo

[3.3.1.13’7]decane.

In a compound of Formula (I), preferably R7 is hydrogen or

alkyl. More preferably, R7 is hydrogen or methyl.
In a compound of Formula (I), preferably R5 is hydrogen.

de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein
m:0; Wherein n:3; Wherein L is iCHZCHZi or 4CECi;

Wherein R1, R2, and R3 are pyridinium rings; Wherein R4 is
45

hydrogen, methyl or forms a phenyl group W1IhAl,A2 and R5 ;

(for example nitrogen, oxygen or sulfur) in the ring, and

Wherein R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2

further may be substituted With one or more substituents. For

pyrrolidinyl, forms a phenyl group With A1, A2 and R4, or
forms a phenyl group With A2, A3 and R6; Wherein R6 is
hydrogen, methyl or forms a phenyl group WithA2, A3 and R5 ;
and Wherein X1, X2, and X3 are Br.
In another embodiment, the compound of Formula (I) is
de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein
m:0; Wherein n:3; Wherein L is iCHZCHZi; Wherein R1,
R2, and R3 are pyridinium rings; Wherein R4 is hydrogen,
methyl or forms a phenyl group With A1, A2 and R5; Wherein

example, possible rings include benZene, pyridine, pyran,
indene, isoindene, benZofuran, isobenZofuran, benZo [b]
thiophene, benZo[c]thiophene, indole, indolenine, isoindole,

cyclopental[b]pyridine, pyrano[3,4-b]pyrrole,

50

indaZole,

indoxaZine, benZoxaZole, anthranil naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,

isochromen-3-one, quinoline, isoquinoline, cinnoline,
quinaZoline, naphthyrdine, pyrido[3,4-b]-pyridine, pyridol
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine,
anthracene, phenanthrene, phenalene, ?uorene, caraZole,
xanthene, acnidine, octahydro-[1]pyridine, 1-methyloctahy
dro-[1]pyridine, octahydroindole, l-methyloctahydroindole,
octahydro-cyclopenta[b]pyrrole, 1-methyloctahydro-cyclo

55

R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidi
nyl, forms a phenyl group With A1, A2 and R4, or forms a

phenyl group With A2, A3 and R6; Wherein R6 is hydrogen,
60

penta[b]pyrrole, decahydroquinoline, and 1-methyldecahyd

roquinoline.
X19, X29, and X39, for example, include F‘, Cl‘, Br‘, I‘,
N02“, HSO4_, SO4_, HPO4_, PO42“, methanesulfonate, tri
?uromethane sulfate, p-toluenesulfonate, benZenesulfonate,

salicylate, proprionate, ascorbate, aspartate, fumarate, galac
tarate, maleate, citrate, glutamate, glycolate, lactate, malate,

65

methyl or forms a phenyl group With A2, A3 and R5; and
Wherein X1, X2, and X3 are Br.
In another embodiment, the compound of Formula (I) is
de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein
m:0; Wherein n:3; Wherein L is 4CECi; Wherein R1, R2,
and R3 are pyridinium rings; Wherein R4 is hydrogen, methyl
or forms a phenyl group With A1, A2 and R5; Wherein R5 is

hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidinyl,
forms a phenyl group With A1, A2 and R4, or forms a phenyl

US 8,299,253 B2
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group With A2, A3 and R6; wherein R6 is hydrogen, methyl or
forms a phenyl group WithA2, A3 and R5 ; and Wherein X1, X2,

(3 -phenyl -pyridinium) -p entyl] -benZene tribromide; 1 ,3 ,5 -

tris-{ 5 -[3 -(1-methyl-2-S-pyrrolidinyl)pyridinium]-pentyl}
benzene tribromide; 1,3,5 -tris- [5 -(1-quinolinium)-pentyl]
benzene tribromide;
1,3,5 -tris-[5 -(2-isoquinolinium)

and X3 are Br.

Exemplary compounds for this application are presented in

pentyl] -benZene tribromide; 1,3, 5-tris-[5-(3 ,5 -lutidinium)

Table 1.
TAB LE 1

R5

I

N@

/ W

L

L W NI(9

R4

/

R5

R4
9

3 Br
L

R4

| \

N (9

R5

/

R7

R6
ID #

R4

R5

R6

R7

L

GZ55OA
GZ55OB
GZ551A
GZ551B

hydrogen
hydrogen
hydrogen
hydrogen

methyl
phenyl
butyl
1-methyl-

hydrogen
hydrogen
hydrogen
hydrogen

hydrogen
hydrogen
hydrogen
hydrogen

4CECi
4CECi
4CECi
4CECi

GZ552A

hydrogen

hydrogen

4C:Ci

GZ552B

phenyl
With R5
hydrogen

phenyl

GZ553A
GZ553B
GZ554A
GZ5 54B
GZ555A
GZ555B
GZ555C
GZ55 6A

hydrogen
hydrogen
methyl
hydrogen
hydrogen
methyl
hydrogen
phenyl

methyl
hydrogen
hydrogen
phenyl

With R5

With R4

GZ556B

hydrogen

2-pyrrolidinyl

GZ557A
GZ557B
GZ55 8A
GZ558B
GZ558C

hydrogen
hydrogen
hydrogen
hydrogen
hydrogen

phenyl
With R4
phenyl
With R6
methyl
methyl
hydrogen
hydrogen

hydrogen

4C:Ci

hydrogen
methyl
hydrogen
methyl
hydrogen
hydrogen
methyl
hydrogen

methyl
hydrogen
hydrogen
hydrogen
hydrogen
hydrogen
hydrogen
hydrogen

4C:Ci
4CECi
4CECi
4CECi
4CH2CH2i
4CH2CH2i
4CH2CH2i
4CH2CH2i

hydrogen

4CH2CH2i

methyl
hydrogen
hydrogen
hydrogen
hydrogen

4CH2CH2i
4CH2CH2i
4CH2CH2i
4CH2CH2i
4CH2CH2i

With R5

phenyl

phenyl

With R6

With R5

methyl
methyl
phenyl
butyl
1-methyl-2-

hydrogen
methyl
hydrogen
hydrogen
hydrogen

pyrroli dinyl

Exemplary compounds of the present invention include: 50 pentyl] -benZene tribromide; and 1,3,5-tris-[5-(3,4
lutidinium)-pentyl] -benZene tribromide.
1,3 ,5 -tris- [5 -(2-picolinium)-pent-1-ynyl]-benZene tribro
The compounds of the present invention may contain one
mide; 1,3,5 -tris- [5 -(3 -picolinium)-pent-1-ynyl]-benZene tri
or
more stereocenters. The invention includes all possible
bromide; 1,3,5 -tris- [5 -(4-picolinium)-pent-1-ynyl]-benZene
diastereomers and all enantiomeric forms as Well as racemic
tribromide; 1,3,5 -tris- [5 -(3 -butyl-pyridinium)-pent-1-ynyl]
benZene tribromide; 1,3,5 -tris- [5 -(3 -phenyl-pyridinium) 55 mixtures. The compounds can be separated into substantially
optically pure compounds.
pent-1-ynyl]-benZene tribromide; 1,3,5 -tris- { 5 -[3 -(1-me
The compounds of the invention are nicotinic acetylcho
thyl-2- S -pyrrolidinyl)pyridinium] -p ent-1 -ynyl} -benZene
line
receptor agents. Thus, they may augment or inhibit [3 H]
tribromide; 1,3,5 -tris- [5 -(1-quinolinium)-pent-1-ynyl]-ben
nicotine binding, [3H]MLA binding, evoke or inhibit neu
Zene tribromide; 1,3,5 -tris- [5 -(2-isoquinolinium)-pent-1 60 rotransmitter release, and/or evoke or inhibit the ?ux of ions
ynyl] -benZene tribromide; 1,3, 5-tris-[5-(3 ,5 -lutidinium)
through the nicotinic receptor. Moreover, the compounds of

pent-1-ynyl]-benZene

tribromide;

1,3,5-tris-[5-(3,4

the invention may act either at presynaptic sites or postsyn

lutidinium) -pent- 1 -ynyl] -benZene tribromide; 1 ,3 ,5 -tris- [5 (2-picolinium)-pentyl] -benZene tribromide; 1,3, 5-tris-[5-(3 -

picolinium) -pentyl] -benZene tribromide; 1,3, 5-tris-[5-(4
picolinium) -pentyl] -benZene tribromide;

aptic sites, for example, at a postsynaptic acetylcholine recep
65

tor containing an (X7 subunit. When acting at a postsynaptic
site, neurotransmitter release per se is not altered. Rather, the

1,3, 5-tris-[5-(3 -

compounds of the invention may act by interacting With a

butyl-pyridinium)-pentyl] -benZene tribromide; 1,3,5 -tris- [5 -

postsynaptic acetylcholine receptor to change the membrane

US 8,299,253 B2
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potential of the cell, thereby increasing or decreasing the
likelihood of ?ring an action potential. Alternatively, interac

dal motor function disorders, Parkinson’s disease, progres

sive supramolecular palsy, Huntington’s disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine dis
orders, dysregulation of food intake, disorders of nociception,
pain, mood and emotional disorders, depression, panic anxi
ety, psychosis, schiZophrenia, or epilepsy.
In yet another embodiment, the present invention is

tion of a compound of the invention With a postsynaptic
acetylcholine receptor may result in the alteration of one or
more second messenger systems Within the cell so as to

decrease or increase the nicotinic cholinergic response.
In one embodiment, the present invention relates to a
method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mam
malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or more

directed to a method for preventing and/ or treating sub stance
use and/or abuse comprising administering to a mammalian
subject in need thereof a therapeutically effective amount of a

compound of Formula (I). In such a method, the compound of
Formula (I) may selectively bind to one or more subtypes of

subtypes of nicotinic acetylcholine receptor. The compound

nicotinic acetylcholine receptor. The compound of Formula

of Formula (I) may act as an agonist or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

tylcholine receptor function. Hence the compound of For

(I) may act as an agonist or partial agonist of nicotinic ace

mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

neurotransmitter from a central nervous system tissue. The

neurotransmitter affected may include dopamine, norepi

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.

Alternatively, the compound of Formula (I) may act as an

20

Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent

Hence the compound of Formula (I) may decrease the extent

or duration of the release of a neurotransmitter from a central

or duration of the release of a neurotransmitter from a central

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans

25

mitter release. The neurotransmitter affected may include

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

dopamine, norepinephrine, serotonin, gamma-aminobutyric

dopamine, norepinephrine, serotonin, gamma-aminobutyric

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

30

increasing or decreasing the likelihood of ?ring an action

increasing or decreasing the likelihood of ?ring an action

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.
In another embodiment, the present invention is directed to

cholinergic response.
35

system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or more

nicotine intoxication, amphetamine abuse, methamphet
40

subtypes of nicotinic acetylcholine receptor. The compound

amine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol
abuse.
In another embodiment, the present invention is directed to
a method for preventing and/or treating gastrointestinal tract

of Formula (I) may act as an against or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a
neurotransmitter from a central nervous system tissue. The

The conditions of substance use and/or abuse treated

according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),

a method for preventing and/or treating a central nervous

disorders comprising administering to a mammalian subject
45

neurotransmitter affected may include dopamine, norepi

in need thereof a therapeutically effective amount of a com

pound of Formula (I). In such a method, the compound of

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.

Formula (I) may selectively bind to one or more subtypes of

Alternatively, the compound of Formula (I) may act as an

nicotinic acetylcholine receptor. The compound of Formula

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent

(I) may act as an agonist or partial agonist of nicotinic ace
50

tylcholine receptor function. Hence the compound of For

55

mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue, or may increase
or prolong the release of a neurotransmitter from a peripheral
nervous system tissue, or may act directly on a gastrointesti
nal tract tissue. The neurotransmitter affected may include

or duration of the release of a neurotransmitter from a central

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

dopamine, norepinephrine, serotonin, gamma-aminobutyric

dopamine, norepinephrine, serotonin, gamma-aminobutyric

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

acid, or glutamate. Alternatively, the compound of Formula
(I) may act as an antagonist of nicotinic acetylcholine recep
tor function. Hence the compound of Formula (I) may

increasing or decreasing the likelihood of ?ring an action

potential, or to alter one or more second messenger systems 60 decrease the extent or duration of the release of a neurotrans
Within the cell so as to decrease or increase the nicotinic
mitter from a central nervous system tissue, or may decrease
the extent or duration of the release of a neurotransmitter from
cholinergic response.
Central nervous system disorders Which may be treated
a peripheral nervous system tissue, or may act directly on a

according to the method of the present invention include

AlZheimer’s disease, dementia, cognitive dysfunctions (in
cluding disorders of attention, focus and concentration),
attention de?cit disorders, affective disorders, extrapyrami

65

gastrointestinal tract tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu
rotransmitter release. The neurotransmitter affected may

include dopamine, norepinephrine, serotonin, gamma-ami
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nobutyric acid, or glutamate. Alternatively, the compound of

Pharmaceutical preparations for oral use canbe obtained as

Formula (I) may act by interacting With a postsynaptic ace

solid excipients, optionally grinding a resulting mixture, and

tylcholine receptor to change the membrane potential of the
cell thereby increasing or decreasing the likelihood of ?ring

processing the mixture of granules, after adding suitable aux

an action potential, or to alter one or more second messenger

excipients are, in particular, ?llers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, Wheat starch, rice starch,

iliaries, if desired, to obtain tablets or dragee cores. Suitable

systems Within the cell so as to decrease or increase the

nicotinic cholinergic response.
Gastrointestinal disorders Which may be treated according

syndrome, colitis, diarrhea, constipation, gastric acid secre

potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcel
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin

tion or ulcers.

tegrating agents may be added, such as the cross-linked poly

to the method of the present invention include irritable boWel

The compounds of the present invention can be delivered

vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as

directly or in pharmaceutical compositions along With suit

sodium alginate. Also, Wetting agents such as sodium dodecyl

able carriers or excipients, as is Well knoWn in the art. For

include a conventional additive, such as a stabilizer, buffer,

sulfate may be included.
Dragee cores are provided With suitable coatings. For this
purpose, concentrated sugar solutions may be used, Which

salt, preservative, ?ller, ?avor enhancer and the like, as knoWn
to those skilled in the art. Exemplary buffers include phos

may optionally contain gum arabic, talc, polyvinyl pyrroli
done, carbopol gel, polyethylene glycol, and/or titanium

example, a pharmaceutical composition of the invention may

phates, carbonates, citrates and the like. Exemplary preserva
tives include EDTA, EGTA, BHA, BHT and the like.

dioxide, lacquer solutions, and suitable organic solvents or
20

An effective amount of such agents can readily be deter
mined by routine experimentation, as can the most effective
and convenient route of administration and the most appro

priate formulation. Various formulations and drug delivery
systems are available in the art. See, e. g., Gennaro, A. R., ed.

25

(1995) Remington’s Pharmaceutical Sciences.
Suitable routes of administration may, for example,

solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identi?cation or to characterize

different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-?t capsules made of gelatin, as Well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-?t capsules can contain the
active ingredients in admixture With ?ller such as lactose,

include oral, rectal, transmucosal, nasal, or intestinal admin

binders such as starches, and/or lubricants such as talc or

istration and parenteral delivery, including intramuscular,

magnesium stearate and, optionally, stabilizers. In soft cap
sules, the active compounds may be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraf?n, or liquid

subcutaneous, intramedullary injections, as Well as intrathe

30

cal, direct intraventricular, intravenous, intraperitoneal, intra

polyethylene glycols. In addition, stabilizers may be added.

nasal, or intraocular injections. In addition, the agent or com
position thereof may be administered sublingually or via a
spray. The agent or composition thereof may be administered
in a local rather than a systemic manner. For example, a

35

suitable agent can be delivered via injection or in a targeted
drug delivery system, such as a depot or sustained release
formulation.

The pharmaceutical compositions of the present invention
may be manufactured by any of the methods Well-knoWn in

40

the art, such as by conventional mixing, dissolving, granulat

ing, dragee-making, levigating, emulsifying, encapsulating,
compositions of the present invention can include one or

istration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in physi
ologically compatible buffers such as Hanks’ solution, Ring
er’ s solution, or physiological saline buffer. For transmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally knoWn in the art. In a preferred embodiment of

tion can be administered transdermally, such as through a skin
patch, or topically. In one aspect, the transdermal or topical
formulations of the present invention can additionally com
prise one or multiple penetration enhancers or other effectors,
including agents that enhance migration of the delivered com
pound. Transdermal or topical administration could be pre

ferred, for example, in situations in Which location speci?c
delivery is desired.
For administration by inhalation, the compounds for use

entrapping, or lyophilizing processes. As noted above, the
more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of admin

All formulations for oral administration should be in dosages
suitable for such administration.
In one embodiment, the compounds of the present inven

45

according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from pressurized
packs or a nebulizer, With the use of a suitable propellant, e. g.,

dichlorodi?uoromethane, trichloro?uoromethane, dichlo
50

rotetra?uoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage
unit may be determined by providing a valve to deliver a

metered amount. Capsules and cartridges of, for example,
gelatin, for use in an inhaler or insuf?ator may be formulated.

These typically contain a poWder mix of the compound and a
55

suitable poWder base such as lactose or starch.

the present invention, the present compounds are prepared in

Compositions formulated for parenteral administration by

a formulation intended for oral administration. For oral

injection, e. g., by bolus injection or continuous infusion can

administration, the compounds can be formulated readily by
combining the active compounds With pharmaceutically
acceptable carriers Well knoWn in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,

be presented in unit dosage form, e.g., in ampoules or in
60

pills, dragees, capsules, liquids, gels, syrups, slurries, suspen

mulatory agents such as suspending, stabilizing and/or dis
persing agents. Formulations for parenteral administration

sions and the like, for oral ingestion by a subject. The com
pounds may also be formulated in rectal compositions such as
suppositories or retention enemas, e.g., containing conven
tional suppository bases such as cocoa butter or other glyc
erides.

multi-dose containers, With an added preservative. The com
positions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain for

65

include aqueous solutions or other compositions in Water
soluble form.

Suspensions of the active compounds may also be prepared

as appropriate oily injection suspensions. Suitable lipophilic

US 8,299,253 B2
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solvents or vehicles include fatty oils such as sesame oil and

A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and thera

synthetic fatty acid esters, such as ethyl oleate or triglycer
ides, or liposomes. Aqueous injection suspensions may con
tain substances that increase the viscosity of the suspension,

peutic e?icacy of such molecules can be determined by stan
dard pharmaceutical procedures in cell cultures or experi
mental animals, e. g., by determining the LD5O (the dose lethal
to 50% of the population) and the ED5O (the dose therapeuti
cally effective in 50% of the population). The dose ratio of
toxic to therapeutic effects is the therapeutic index, Which can
be expressed as the ratio LDSO/EDSO. Agents that exhibit high
therapeutic indices are preferred.
Dosages preferably fall Within a range of circulating con

such as sodium carboxymethyl cellulose, sorbitol, or dextran.

Optionally, the suspension may also contain suitable stabiliZ
ers or agents that increase the solubility of the compounds to

alloW for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in poWder form for
constitution With a suitable vehicle, e.g., sterile pyrogen-free
Water, before use.

As mentioned above, the compositions of the present
invention may also be formulated as a depot preparation.

centrations that includes the ED5O With little or no toxicity.

Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscu
larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated With suitable poly
meric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.

20

Suitable carriers for the hydrophobic molecules of the

Dosages may vary Within this range depending upon the
dosage form employed and the route of administration uti
liZed. The exact formulation, route of administration, and
dosage should be chosen, according to methods known in the
art, in vieW of the speci?cs of a subject’s condition.
The amount of agent or composition administered Will, of
course, be dependent on a variety of factors, including the sex,

invention are Well known in the art and include co-solvent

age, and Weight of the subject being treated, the severity of the

systems comprising, for example, benZyl alcohol, a nonpolar

af?iction, the manner of administration, and the judgment of

surfactant, a Water-miscible organic polymer, and an aqueous
phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% W/v benZyl alcohol, 8% W/v

the prescribing physician.
25

of the nonpolar surfactant polysorbate 80, and 65% W/v poly
ethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPD15W) consists of VPD
diluted 1:1 With a 5% dextrose in Water solution. This co

30

solvent system is effective in dissolving hydrophobic com

pounds and produces loW toxicity upon systemic administra
tion. Naturally, the proportions of a co-solvent system may be

varied considerably Without destroying its solubility and tox
icity characteristics. Furthermore, the identity of the co-sol

The present compositions may, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
may, for example, comprise metal or plastic foil, such as a

35

vent components may be varied. For example, other loW
toxicity nonpolar surfactants may be used instead of

blister pack. The pack or dispenser device may be accompa
nied by instructions for administration. Compositions com
prising a compound of the invention formulated in a compat
ible pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indi
cated condition.
These and other embodiments of the present invention Will
readily occur to those of ordinary skill in the art in vieW of the

disclosure herein, and are speci?cally contemplated.

polysorbate 80, the fraction siZe of polyethylene glycol may

be varied, other biocompatible polymers may replace poly
ethylene glycol, e. g., polyvinyl pyrrolidone, and other sugars

EXAMPLES

40

or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic mol
ecules may be employed. Liposomes and emulsions are Well
knoWn examples of delivery vehicles or carriers for hydro

phobic drugs. Liposomal delivery systems are discussed

45

above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also may be

illustrations of single aspects of the invention only. Any meth

employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sus
tained-release systems, such as semi-permeable matrices of

The invention is further understood by reference to the
folloWing examples, Which are intended to be purely exem
plary of the invention. The present invention is not limited in
scope by the exempli?ed embodiments, Which are intended as

50

solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustained

ods that are functionally equivalent are Within the scope of the
invention. Various modi?cations of the invention in addition
to those described herein Will become apparent to those
skilled in the art from the foregoing description. Such modi
?cations fall Within the scope of the appended claims.

release materials are established and available to those of skill

in the art. Sustained-release capsules may, depending on their
chemical nature, release the compounds for a feW Weeks up to
over 100 days. Depending on the chemical nature and the

Example 1
55

Preparation of

biological stability of the therapeutic reagent, additional
strategies for stabiliZation may be employed.

1,3 , 5-tris-(5 -hydroxypent-1-ynyl)-benZene

For any composition used in the present methods of treat
ment, a therapeutically effective dose can be estimated ini

60

tially using a variety of techniques Well knoWn in the art. For

Br

example, in a cell culture assay, a dose can be formulated in
animal models to achieve a circulating concentration range

that includes the lC5O as determined in cell culture. Dosage
ranges appropriate for human subjects can be determined, for
example, using data obtained from cell culture assays and
other animal studies.

65
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-continued

dissolved in dry methylene chloride (40 mL) and cooled to 00
C. Triphenyl phosphine (6.16 g, 23.47 mmol) Was added

%

%

OH

dropWide and the mixture Was stirred at 0° C. for 30 minutes.

The mixture Was poured into hexanes (200 mL), ?ltered
through a short silica gel column and Washed With ethyl
acetate/hexanes (1/4). The combined organic solvents Were
evaporated to dryness under reduced pressure. The resulting

residue Was puri?ed by column chromatography (hexanes:
ethyl acetate 10:1) to afford 2.63 g of 1,3,5-tris-(5-bro

mopent-1-ynyl)-benZene. Yield 89%. 1H NMR (300 MHZ,
CDCl3) 6 7.33 (s, 3H), 3.57 (t, 1:63 HZ), 2.60 (t, 1:69 HZ,
6H), 2.12 (m, 6H) ppm; 13C NMR (75 MHZ, CDCl3) 6 133.9,
124.1, 89.2, 80.4, 32.6, 31.7, 18.4 ppm.
OH

Example 3

1,3,5-TribromobenZene (10 g, 31.76 mmol), 4-pentyn-1-ol
(10.69 g, 127.06 mmol) and bis(triphenylphosphine)palla
dium(ll) dichloride Were stirred in triethylamine under nitro
gen for 5 minutes. Copper(l) iodide (92 mg, 0.48 mmol) Was

Preparation of 1 ,3 ,5 -tris -(5 -hydroxypentyl) -b enZene
20

added and the mixture Was stirred for 6 hours at 80° C. The
mixture Was cooled to room temperature, ?ltered through a

celite pad and rinsed With ethyl acetate. The combined ?ltrate
Was evaporated to dryness under reduced pressure. The

resulting residue Was puri?ed by column chromatography
(CHCl3:MeOH 10:1) to afford 7.61 g of 1,3,5-tris-(5-hy
droxy-1-pentynyl)-benZene. Yield: 74%. 1H NMR (300
MHZ, CDCl3) 6 7.31 (3, 3h), 3.81 (t, 1:60 HZ, 6H), 2.52 (t,
1:69 HZ, 6H), 1.85 (m, 6H); 13C NMR (75 MHZ, CDCl3) 6
133.8, 124.2, 90.5, 80.0, 61.9, 31.5, 16.2 ppm.

HO

%

%

OH

30

H
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Example 2

Preparation of

35

1,3 ,5 -tris-(5 -bromopent-1-ynyl)-benZene

HO

%

OH

%

40

HO

OH

45

OH
50

Br

1,3,5 -tris-(5 -hydroxy-1-pentynyl)-benZene (2. 84 g, 8 .6
mmol) Was dissolved in methanol (30 mL) and 10% Pd/C (5%
W/W) Was added. The resulting mixture Was hydrogenated on

a Parr hydrogenation apparatus (45 psi) for 4 hours. The
catalyst Was removed by ?ltration through a celite pad. The
60

Br
65

1,3,5-tris-(5-hydroxy-1-pentynyl)-benZene (1.86 g, 5.73
mmol) and carbon tetrabromide (7.41 g, 22.35 mmol) Were

?lter cake Was rinsed With methanol, and the combined
organic liquors Were concentrated under reduced pressure.

The crude product Was puri?ed by column chromatography
(CHCl3:MeOH 6:1) to afford 2.84 g of 1 ,3,5-tris-(5-hydroxy
pentyl)-benZene. Yield 96%. 1H NMR (300 MHZ, CDCl3) 6
6.81 (s, 3H), 3.62 (t, 1:63 HZ, 6H), 2.57 (t, J:7.5 HZ, 6H),
1.53-1.70 (m, 12H), 1.38 (m, 6H) ppm; 13C NMR (75 MHZ,
CDCl3) 6 142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm.

US 8,299,253 B2
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Example 4
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Preparation of 1,3,5-tris-(5 -bromopentyl)-benZene
\

\
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HO
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3Br
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A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene

Br

(223 mg, 0.43 mmol) and 2-picoline (607 mg, 6.52 mmol)
Was heated at 60-700 C. for 12 hours. The resultant mixture
20

Was Washed With diethyl ether and then dissolved in Water (15
mL), the aqueous solution Was Washed With diethyl ether,

then lyophiliZed to afford 327 mg of 1,3,5-tris-[5-(2-pi
colinium)-pent-1-ynyl]-benZene tribromide. Yield 95%. H
25

NMR (300 MHZ, CD3OD) 6 9.01 (dd, 1:63, 0.9 HZ, 3H),
8.44 (dt, J:7.8, 1.5 HZ, 3H), 7.92-8.07 (m, 6H), 7.41 (s, 3H),
4.81 (t, 1:60 HZ), 2.98 (s, 9H), 2.70 (t, J:7.2 HZ, 6H), 2.29
(m, 6H) ppm; 13C NMR (75 MHZ, CD3OD) 6 157.1, 146.8,
146.6, 134.9, 131.6, 127.1, 125.4, 90.1, 81.6, 58.4, 299,207,
17.3 ppm.

Preparation of 1,3,5-tris-(5 -bromopentyl)-benZene

Example 6

1,3,5-tris-(5-hydroxypentyl)-benZene (2.83 g, 8.41 mmol)

Preparation of

and carbon tetrabromide (10.99 g, 32.80 mmol) Were dis

1,3,5-tris-[5-(3-picolinium)-pent-1-ynyl]-benZene

solved in dry methylene chloride (50 mL) and cooled to 0° C.
Triphenyl phosphine (9.03 g, 34.33 mmol) Was added drop

tribromide

Wise and the mixture Was stirred for 30 minutes at 00 C. The

mixture Was poured into hexanes (250 mL), ?ltered through a
short silica gel column and Washed With ethyl acetate/hexanes
(1/4). The combined organic solvents Were evaporated to
dryness under reduced pressure. The resulting residue Was

Br

%

%

Br

puri?ed by column chromatography (hexaneszethyl acetate
8:1) to afford 4.08 g of 1,3,5-tris-(5-bromopentyl)-benZene.

Yield 92%. 1H NMR (300 MHZ, CDCl3) 6 6.81 (s, 3h), 3.41
(t, J:6.9 HZ, 6H), 2.60 (t, 1:75 HZ, 6H), 1.88 (m, 6H), 1.45
(m, 6H) ppm; 13C NMR (75 MHZ, CDCl3) 6 142.4, 126.1,
35.9, 34.2, 32.9, 30.9, 28.2 ppm.

—>

45

Example 5
Br

Preparation of

1,3, 5-tris-[5-(2 -picolinium)-pent-1 -ynyl] -benZene

/

tribromide
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Br

A mixture of 1,3 ,5 -tris-(5 -bromopent-1-ynyl)-benZene
(256 mg, 0.50 mmol) and 3-picoline (690 mg, 7.50 mmol)
Was heated at 60-700 C. for 12 hours. The resultant mixture

US 8,299,253 B2
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Was Washed With diethyl ether (30 mL><3) and then dissolved
in Water (15 mL), the aqueous solution Was Washed With
diethyl ether, then lyophiliZed to afford 345 mg of 1,3,5-tris
[5-(3-picolinium)-pent-1-ynyl]-benZene tribromide. Yield

@3013) 6 161.5, 145.2, 134.9, 130.0, 125.4, 90.0, 81.4, 61.6,

87%. 1H NMR (300 MHZ, CD3OD) 6 9.02 (s, 3H), 8.92 (d,
J:6.0 HZ, 3H), 8.4 (d, J:8.4 HZ, 3H), 8.01 (dd, 1:81, 6.0 HZ,
3H), 7.35 (s, 3H), 4.81 (t, J:7.2 HZ, 6H), 2.64 (t, 1:69 HZ,
6H), 2.58 (s, 9H), 2.35 (m, 6H) ppm; 13C NMR (75 MHZ,
CD3OD) 6 147.5, 145.8, 143.4, 141.3, 134.9, 128.8, 125.3,
89.9, 81.5, 62.2, 31.0, 18.7, 17.2 ppm.

30.8, 22.2, 17.2 ppm.
5

Example 8

Preparation of 1,3 ,5 -tris- [5 -(3 -butyl-pyridinium)
pent-1 -ynyl] -benZene tribromide

Example 7

Preparation of

Br

1,3, 5-tris-[5-(4 -picolinium)-pent-1 -ynyl] -benZene
tribromide

%

%

Br
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A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene

(240 mg, 0.47 mmol) and 3-butyl pyridine (950 mg, 7.05
mmol) Was heated at 60-700 C. for 12 hours. The resultant
mixture Was Washed With diethyl ether and then dissolved in
55

Water (15 mL), the aqueous solution Was Washed With diethyl
ether (30 mL><3), then lyophiliZed to afford 254 mg of 1,3,5

60

tris-[5-(3 -butyl-pyridinium) -pent- 1 -ynyl] -benZene tribro
mide. Yield 59%. 1H NMR (300 MHZ, CD3OD) 6 9.04 (s,
3H), 8.94 (d, 1:60 HZ, 3H), 8.44 (d, J:8.1 HZ, 3H), 8.04 (dd,
1:81, 6.0 HZ, 3H), 7.33 (s, 3H), 4.82 (t, J:7.2 HZ, 6H), 2.87
(t, J:7.8 HZ, 6H), 2.63 (t, 1:69 HZ, 6H), 2.35 (m, 6H), 1.69
(m, 6H), 1.42 (m, 6H), 0.97 (t, 1:75 HZ, 9H) ppm; 13C NMR

65

(75 MHZ, CD3OD) 6 146.8, 145.8, 145.6, 143.6, 135.0,
129.0, 125.3, 89.9, 81.5, 62.2, 33.8, 33.5, 30.9, 23.5, 17.2,

A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene

(210 mg, 0.41 mmol) and 4-picoline (572 mg, 6.14 mmol)
Was heated at 60-700 C. for 12 hours. The resultant mixture

Was Washed With diethyl ether and then dissolved in Water (1 5
mL), the aqueous solution Was Washed With diethyl ether (30

mL><3), then lyophiliZed to afford 316 mg of 1 ,3,5-tris-[5-(4

picolinium)-pent-1 -ynyl] -benZene tribromide.Yield 97%. 1H
NMR (300 MHZ, CD3OD) 8.91 (dd, 1:51, 1.8 HZ, 6H), 7.94
(d, 1:63 HZ, 6H), 4.77 (t, 1:69 HZ, 6H), 2.63 (t, 1:66 HZ,
6H), 2.62 (s, 9H), 2.33 (m, 6H) ppm; 13C NMR (75 MHZ,

14.3 ppm.

US 8,2 99,253 B2
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Example 9
Preparation of 1 ,3, 5 -tris - [ 5 - (3 -phenyl -pyridinium) -

pent- 1 -ynyl] -benZene tribromide

BI

%

%

Br

ll
Br

A mixture of 1,3,5-tris-(5 -bromopent-1-ynyl)-benZene 40 7.17 (s, 3H), 4.96 (1, 1:69 HZ, 6H), 2.69 (1, 1:63 HZ, 6H),
(259 mg, 0.50 mmol) and 3-phenyl pyridine (1.18 g, 7.50
2.42 (m, 6H) ppm; 13C NMR (75 MHZ, CD3OD) 0 144.4,
mmol) Was heated at 60-700 C. for 12 hours. The resultant
144.3,144.2,1426,134.9,134.5,131.5,130.8,129.5,128.7,
mixture Was Washed With diethyl ether and then dissolved in
125.1, 90.0, 81.5, 62.6, 30.8, 17.4 ppm.
Water (15 mL), the aqueous solution Was Washed With diethyl
ether (30 mL><5), then lyophiliZed to afford 415 mg of 1,3,5 45

Example 10

tris - [ 5 -(3 -phenyl-pyridinium) -p ent-1 -ynyl] -b enZene tribro -

mide. Yield 85%. 1H NMR (300 MHZ, CD3OD) 6 9.50 (s,
3H), 9.09 (d, 1:60 HZ, 3H), 8.78 (d, J:8.1 HZ, 3H), 8.16 (dd,

Preparation of 1,3,5-tris-{5-[3-(1-methyl-2-S-pyrro

1:81, 6.0 HZ, 3H), 7.75-7.87 (m, 6H), 7.42-7.65 (m, 9H),

lidinyl)pyridinium] -p ent-1 -ynyl} -benZene tribromide

//

\\

Br

Br
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A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene
(246 mg, 0.48 mmol) and S-nicotine (1.5 mL) Was heated at

-continued
30

60-700 C. for 12 hours. The resultant mixture Was Washed

With diethyl ether and then dissolved in Water (15 mL), the
aqueous solution Was Washed With diethyl ether (30 mL><5),
then lyophiliZed to afford 440 mg of 1,3,5-tris-{5-[3-(1-me
thyl-2- S -pyrrolidinyl)pyridinium] -p ent-1 -ynyl} -benZene tri
bromide.Yield 92%. 1H NMR (300 MHZ, CD3OD) 6 9.16 (s,

3H), 9.02 (d, 1:60 HZ, 3H), 8.60 (d,j:8.1 HZ, 3H), 8.12 (dd,
J:8.1, 6.0 HZ, 3H), 7.40 (s, 3H), 4.86 (t, 1:69 HZ, 6H), 3.69
(m, 3H), 3.32 (m, 6H), 2.14-2.70 (m, 12H), 2.33 (s, 9H),
1.73-2.14 (m, 10H) ppm; 13C NMR (75 MHZ, CD3OD) 6
146.2, 145.4, 145.0, 135.1, 129.5, 125.3, 89.8, 81.8, 68.8,
62.3, 58.0, 40.8, 36.0, 30.8, 24.1, 17.1 ppm.
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Example 11

\

Preparation of
1,3 ,5 -tris- [5 -(1-quinolinium)-pent-1-ynyl]-benZene
tribromide

A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene
(232 mg, 0.45 mmol) and quinoline (880 mg, 6.75 mmol) Was
heated at 60-700 C. for 12 hours. The resultant mixture Was
55

Br
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Br
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Br

Washed With diethyl ether and then dissolved in Water (15
mL), the aqueous solution Was Washed With diethyl ether (30
mL><5), then lyophiliZed to afford 234 mg of 1,3,5-tris-[5-(1
quinolinium)-pent-1-ynyl]-benZene tribromide. Yield 58%.

1H NMR (300 MHZ, CD3OD) 6 9.58 (dd, 1:60, 4.5 HZ, 3H),
9.18 (d, J:8.1 HZ, 3H), 8.67, d, 1:90 HZ, 3H), 8.41 (dd,
1:81, 1.8 HZ, 3H), 8.31 (m, 3H), 7.98-8.18 (m, 6H), 7.11 (s,
3H), 5.32 (t, 1:69 HZ, 6H), 2.75 (t, 1:66 HZ, 6H), 2.46 (m,
6H) ppm; 13C NMR (75 MHZ, CD3OD) 6 150.9, 149.3,
139.6,137.4,134.8,132.3,131.8,131.4,125.2,123.2,119.8,
90.2, 81.4, 58.8, 29.6, 17.5 ppm.
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eExample 12

Preparation of 1,3,5-tris-[5-(2-isoquino1inium)-pent
1 -yny1] -benZene tribromide
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A mixture of 1,3,5-tris-(5 -bromopent-1-yny1)-benZene 50

(222 mg, 0.43 mmol) and isoquinoline (840 mg, 6.45 mmol)
Was heated at 60-700 C. for 12 hours. The resultant mixture

Example 13

Preparation of 1,3 ,5 -tris- [5 -(3 ,5 -1utidinium)-pent-1
ynyl] -benZene tribromide

Was Washed With diethyl ether and then dissolved in Water (1 5

mL), the aqueous so1ution Was Washed With diethyl ether (30 55 Br

%

%

mL><5), then 1yoph111Zed to afford 357 mg of 1 ,3,5-tr1s-[5-(2
isoquino1inium)-pent-1-yny1]-benZene tribromide. Yield

92%.1H NMR (300 MHZ, CD3OD) 6 10.15 (s, 3H), 8.79 (dd,

1:69, 1.2 HZ, 3H), 8.67, d, 1:90 HZ, 3H), 8.50 (m, 3H), 8.20
(m, 6H), 8.06 (m, 3H), 6.54 (s, 3H), 5.00 (t, 1:69 HZ, 6H),
2.75 (t, 1:63 HZ, 6H), 2.47 (m, 6H) ppm; 13C NMR (75 MHZ,
CD3OD) 6 151.5, 139.2, 138.5, 136.0, 134.1, 132.6, 131.6,
129.2, 128.4, 127.5, 124.7, 90.0, 81.2, 62.6, 30.5, 17.6

H

Br

Br

